Top

Published in:

01-12-2020 | Prostate Cancer | Original Research

Dosimetric correlations with urinary quality of life in patients receiving post-prostatectomy radiation therapy

Authors: Kevin A. Pearlstein, Srinivas Saripalli, Ram Basak, Jasmine Sun, John Dooley, Xianming Tan, Andrew Z. Wang, Ronald C. Chen, Panayiotis Mavroidis

Published in: Journal of Radiation Oncology | Issue 3-4/2020

Abstract

Objective

Acute urinary toxicity is well-documented in individuals receiving post-prostatectomy radiation. However, dosimetric correlations between bladder dose and acute urinary symptoms in the post-prostatectomy setting have not been well-studied. We examined the relationship between bladder dosimetry and acute changes in individual urinary symptoms among men receiving post-prostatectomy radiation therapy.

Methods

Patient-reported urinary symptoms were prospectively collected for 90 consecutive prostate cancer patients receiving post-prostatectomy radiation using the validated quality of life instrument Prostate Cancer Symptom Indices. Data were collected prior to treatment and weekly during treatment. Individual symptom scores were examined and a change in severity of an individual symptom (from baseline) of ≥ 2 points was considered clinically significant. DVHs were generated for all the patients. Receiver operating characteristic curves were generated to evaluate the ability of different dose-volume metrics to identify patients who developed individual urinary symptoms during radiation treatment from those who did not. Logistic regression was used to examine the relationship between dose-volume parameters and worsening of individual urinary symptoms.

Results

Worsening of individual urinary symptoms during radiation treatment was reported by 7% (urinary flow) to 29% (urgency) of patients. The relative bladder volume receiving moderate doses of radiation was associated with urgency (AUC 0.67 for V30 Gy). Dose-volume parameters were not significantly associated with flow, frequency, nocturia, or dysuria.

Conclusion

There is an acute worsening of urinary symptoms among men receiving modern post-prostatectomy radiation. Worsening of urgency is associated with bladder dosimetry while flow, frequency, nocturia, and dysuria are not. This data can be used during treatment planning to reduce acute urinary toxicity during post-prostatectomy radiation.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30CrossRef

Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued rise of biochemical failure after 5 years. J Urol 164:101–105CrossRef

Bianco FJ, Scardino PT, Eastham JA (2005) Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 66:83–94CrossRef

Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW (2005) Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23:7005–7012CrossRef

Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578CrossRef

Moinpour CM, Hayden KA, Unger JM, Thompson IM Jr, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED, Southwest Oncology Group (2008) Health-related quality of life results in pathologic stage C prostate cancer from a southwest oncology group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 26:112–120CrossRef

Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weißbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930CrossRef

Boersma LJ, van den Brink M, Bruce AM et al (1998) Estimation of the incidence of late bladder and rectum complications after high-dose (70-78Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 41:83–92CrossRef

Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE (1997) Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 37:3–11CrossRef

10.

Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Pollack A, Kestin LL, Valicenti RK, DeWeese TL, Sandler HM (2007) Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 68:1417–1423CrossRef

11.

Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer - a randomized clinical trial. JAMA 296:2329–2335CrossRef

12.

Fiorino C, Valdagni R, Rancati T, Sanguineti G (2009) Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol 93:153–167CrossRef

13.

Palorini F, Rancati T, Cozzarini C, Improta I, Carillo V, Avuzzi B, Casanova Borca V, Botti A, Degli Esposti C, Franco P, Garibaldi E, Girelli G, Iotti C, Maggio A, Palombarini M, Pierelli A, Pignoli E, Vavassori V, Valdagni R, Fiorino C (2016) Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. Radiother Oncol 118:92–98CrossRef

14.

Cozzarini C, Rancati T, Carillo V, Civardi F, Garibaldi E, Franco P, Avuzzi B, Esposti CD, Girelli G, Iotti C, Palorini F, Vavassori V, Valdagni R, Fiorino C (2015) Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: results of a cohort study. Radiother Oncol 116:185–191CrossRef

15.

Carillo V, Cozzarini C, Rancati T, Avuzzi B, Botti A, Borca VC, Cattari G, Civardi F, Esposti CD, Franco P, Girelli G, Maggio A, Muraglia A, Palombarini M, Pierelli A, Pignoli E, Vavassori V, Zeverino M, Valdagni R, Fiorino C (2014) Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer. Radiother Oncol 111:100–105CrossRef

16.

Chen RC, Clark JA, Talcott JA (2009) Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 27:3916–3922CrossRef

17.

Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261CrossRef

18.

Clark JA, Talcott JA (2001) Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care 39:1118–1130CrossRef

19.

Chen RC, Basak R, Meyer AM, Kuo TM, Carpenter WR, Agans RP, Broughman JR, Reeve BB, Nielsen ME, Usinger DS, Spearman KC, Walden S, Kaleel D, Anderson M, Stürmer T, Godley PA (2017) Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA 317:1141–1150CrossRef

20.

Mavroidis P, Pearlstein KA, Dooley J, Sun J, Saripalli S, Das SK, Wang AZ, Chen RC (2018) Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy. Radiat Oncol 13:17CrossRef

21.

Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70:1124–1129CrossRef

22.

Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU (2010) Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 76:S116–S122CrossRef

23.

Jereczek-Fossa BA, Zerini D, Fodor C, Santoro L, Serafini F, Cambria R, Vavassori A, Cattani F, Garibaldi C, Gherardi F, Ferrari A, Rocco B, Scardino E, de Cobelli O, Orecchia R (2010) Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy. Int J Radiat Oncol Biol Phys 78:26–34CrossRef

24.

Michalski JM, Yan Y, Watkins-Bruner D, Walter B, Winter K, Galvin JM, Bahary J, Morton GC, Parliament MB, Sandler H (2011) Preliminary analysis of 3D-CRT vs. IMRT on the high dose arm of the RTOG 0126 prostate cancer trial: toxicity report. Int J Radiat Oncol Biol Phys 81:S1–S2CrossRef

25.

Ali AN, Rossi PJ, Godette KD, Martin D, Liauw S, Vijayakumar S, Cooper S, Jani AB (2013) Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity modulated radiation therapy. Pract Radiat Oncol 3:e1–e9CrossRef

26.

Diao K, Lobos EA, Yirmibesoglu E, Basak R, Hendrix LH, Barbosa B, Miller SM, Pearlstein KA, Goldin GH, Wang AZ, Chen RC (2017) Patient-reported quality of life during definitive and postprostatectomy image-guided radiation therapy for prostate cancer. Pract Radiat Oncol 7:e117–e124CrossRef

27.

Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC, Plasswilm L, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbühler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Kaouthar K, Wust P, Thalmann GN, Aebersold DM (2015) Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol 33:4158–4166CrossRef

28.

Yahya N, Ebert MA, Bulsara M, Haworth A, Kennedy A, Joseph DJ, Denham JW (2015) Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: an analysis of data from the RADAR prostate radiotherapy trial. Radiother Oncol 116:112–118CrossRef

29.

Peeters STH, Hoogeman MS, Heemsbergen WD, Slot A, Tabak H, Koper PCM, Lebesque JV (2005) Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 63:1142–1152CrossRef

30.

Akthar AS, Liao C, Eggener SE, Liauw SL (2019) Patient-reported outcomes and late toxicity after postprostatectomy intensity-modulated radiation therapy. Eur Urol 76:686–692CrossRef

31.

Iyengar P, Levy LB, Choi S, Lee AK, Kuban DA (2011) Toxicity associated with postoperative radiation therapy for prostate cancer. Am J Clin Oncol 34:611–618CrossRef

32.

Cheng JC, Schultheiss TE, Nguyen KH, Wong JY (2008) Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 71:351–357CrossRef

33.

Chen RC, Mamon HJ, Chen YH, Gelman RS, Suh WW, Talcott JA, Clark JW, Hong TS (2010) Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer. Cancer 116:1879–1886CrossRef

34.

Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865–869CrossRef

35.

Pisansky T, Thompson I, Valicenti R et al (2019) Adjuvant and salvage radiation therapy after prostatectomy: ASTRO/AUA guideline amendment, executive summary 2018. Practical Radiat Oncol 9:208–213CrossRef

36.

Yahya N, Ebert MA, House MJ et al (2017) Modeling urinary dysfunction after external beam radiation therapy of the prostate using bladder dose-surface maps: evidence of spatially variable response of the bladder surface. Int J Radiat Oncol Biol Phys 97:420–426CrossRef

37.

Ghadjar P, Zelefsky MJ, Spratt DE, Munck af Rosenschöld P, Oh JH, Hunt M, Kollmeier M, Happersett L, Yorke E, Deasy JO, Jackson A (2014) Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 88:339–344CrossRef

Title: Dosimetric correlations with urinary quality of life in patients receiving post-prostatectomy radiation therapy
Authors: Kevin A. Pearlstein
Srinivas Saripalli
Ram Basak
Jasmine Sun
John Dooley
Xianming Tan
Andrew Z. Wang
Ronald C. Chen
Panayiotis Mavroidis
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Prostatectomy
Prostatectomy
Published in: Journal of Radiation Oncology / Issue 3-4/2020
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-020-00426-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3-4/2020

Impact of lung tumor motion on dose delivered to organ at risk in lung stereotactic body radiation therapy

Efficacy of palliative SBRT in local control of sarcoma

Dosimetric comparison of linac-based modulated techniques for hippocampal sparing whole brain radiotherapy

SBRT re-irradiation after prior SBRT in pancreatic cancer—outcomes and a focus on stomach and bowel toxicity

Brain metastases from small cell lung cancer: survival after whole brain radiotherapy versus stereotactic radiosurgery of recursive partitioning analysis class I–II patients

Feasibility of simulation contrast-enhanced computed tomography (CECTSim) of the head and neck region to detect early nodal recurrence in postoperative oral squamous cell carcinoma in a resource-constrained setup

Keynote webinar | Spotlight on antibody–drug conjugates in cancer